I can start.
Before I do, there has been a slight implication that Canada is free-riding in the pharmaceutical sector. Nothing could be further from the truth.
We have a very strong patent regime, a very strong data exclusivity regime. We provide eight years of data protection in Canada, far more than they do in the United States. We don't incent generics to come to market and challenge patents the way they do in the United States. In the United States if you're the first generic to challenge a patent, you get six months of exclusivity. They build it into their law that generics should challenge patents and make sure that only valid patents protect competition and keep prices high.
The last point I'd make is that patents are geographic neutral, but because of the nature of national treatment you will get the same protection in Canada whether you do the research in Mumbai, Munich, New York, or New Jersey. It doesn't incent you to come to Montreal, Toronto, or Vancouver to do the research. In Canada we've seen a decline in research and development. There are things Canada could do to attract more research and development. Simply increasing patent protection is going to increase profits of companies that are doing research out of Canada. That is going to be the primary impact.